Cargando…

Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis

BACKGROUND: Multiple sclerosis (MS) has been mainly attributed to white matter (WM) pathology. However, recent evidence indicated the presence of grey matter (GM) lesions. One of the principal mediators of inflammatory processes is interleukin-1β (IL-1β), which is known to play a role in MS pathogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Prins, Marloes, Eriksson, Charlotta, Wierinckx, Anne, Bol, John G. J. M., Binnekade, Rob, Tilders, Fred J. H., Van Dam, Anne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871572/
https://www.ncbi.nlm.nih.gov/pubmed/24376764
http://dx.doi.org/10.1371/journal.pone.0083835
_version_ 1782296837896536064
author Prins, Marloes
Eriksson, Charlotta
Wierinckx, Anne
Bol, John G. J. M.
Binnekade, Rob
Tilders, Fred J. H.
Van Dam, Anne-Marie
author_facet Prins, Marloes
Eriksson, Charlotta
Wierinckx, Anne
Bol, John G. J. M.
Binnekade, Rob
Tilders, Fred J. H.
Van Dam, Anne-Marie
author_sort Prins, Marloes
collection PubMed
description BACKGROUND: Multiple sclerosis (MS) has been mainly attributed to white matter (WM) pathology. However, recent evidence indicated the presence of grey matter (GM) lesions. One of the principal mediators of inflammatory processes is interleukin-1β (IL-1β), which is known to play a role in MS pathogenesis. It is unknown whether IL-1β is solely present in WM or also in GM lesions. Using an experimental MS model, we questioned whether IL-1β and the IL-1 receptor antagonist (IL-1ra) are present in GM in addition to affected WM regions. METHODS: The expression of IL-1β and IL-1ra in chronic-relapsing EAE (cr-EAE) rats was examined using in situ hybridization, immunohistochemistry and real-time PCR. Rats were sacrificed at the peak of the first disease phase, the trough of the remission phase, and at the peak of the relapse. Histopathological characteristics of CNS lesions were studied using immunohistochemistry for PLP, CD68 and CD3 and Oil-Red O histochemistry. RESULTS: IL-1β and IL-ra expression appears to a similar extent in affected GM and WM regions in the brain and spinal cord of cr-EAE rats, particularly in perivascular and periventricular locations. IL-1β and IL-1ra expression was dedicated to macrophages and/or activated microglial cells, at sites of starting demyelination. The time-dependent expression of IL-1β and IL-1ra revealed that within the spinal cord IL-1β and IL-1ra mRNA remained present throughout the disease, whereas in the brain their expression disappeared during the relapse. CONCLUSIONS: The appearance of IL-1β expressing cells in GM within the CNS during cr-EAE may explain the occurrence of several clinical deficits present in EAE and MS which cannot be attributed solely to the presence of IL-1β in WM. Endogenously produced IL-1ra seems not capable to counteract IL-1β-induced effects. We put forward that IL-1β may behold promise as a target to address GM, in addition to WM, related pathology in MS.
format Online
Article
Text
id pubmed-3871572
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38715722013-12-27 Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis Prins, Marloes Eriksson, Charlotta Wierinckx, Anne Bol, John G. J. M. Binnekade, Rob Tilders, Fred J. H. Van Dam, Anne-Marie PLoS One Research Article BACKGROUND: Multiple sclerosis (MS) has been mainly attributed to white matter (WM) pathology. However, recent evidence indicated the presence of grey matter (GM) lesions. One of the principal mediators of inflammatory processes is interleukin-1β (IL-1β), which is known to play a role in MS pathogenesis. It is unknown whether IL-1β is solely present in WM or also in GM lesions. Using an experimental MS model, we questioned whether IL-1β and the IL-1 receptor antagonist (IL-1ra) are present in GM in addition to affected WM regions. METHODS: The expression of IL-1β and IL-1ra in chronic-relapsing EAE (cr-EAE) rats was examined using in situ hybridization, immunohistochemistry and real-time PCR. Rats were sacrificed at the peak of the first disease phase, the trough of the remission phase, and at the peak of the relapse. Histopathological characteristics of CNS lesions were studied using immunohistochemistry for PLP, CD68 and CD3 and Oil-Red O histochemistry. RESULTS: IL-1β and IL-ra expression appears to a similar extent in affected GM and WM regions in the brain and spinal cord of cr-EAE rats, particularly in perivascular and periventricular locations. IL-1β and IL-1ra expression was dedicated to macrophages and/or activated microglial cells, at sites of starting demyelination. The time-dependent expression of IL-1β and IL-1ra revealed that within the spinal cord IL-1β and IL-1ra mRNA remained present throughout the disease, whereas in the brain their expression disappeared during the relapse. CONCLUSIONS: The appearance of IL-1β expressing cells in GM within the CNS during cr-EAE may explain the occurrence of several clinical deficits present in EAE and MS which cannot be attributed solely to the presence of IL-1β in WM. Endogenously produced IL-1ra seems not capable to counteract IL-1β-induced effects. We put forward that IL-1β may behold promise as a target to address GM, in addition to WM, related pathology in MS. Public Library of Science 2013-12-23 /pmc/articles/PMC3871572/ /pubmed/24376764 http://dx.doi.org/10.1371/journal.pone.0083835 Text en © 2013 Prins et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Prins, Marloes
Eriksson, Charlotta
Wierinckx, Anne
Bol, John G. J. M.
Binnekade, Rob
Tilders, Fred J. H.
Van Dam, Anne-Marie
Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis
title Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis
title_full Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis
title_fullStr Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis
title_full_unstemmed Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis
title_short Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis
title_sort interleukin-1β and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871572/
https://www.ncbi.nlm.nih.gov/pubmed/24376764
http://dx.doi.org/10.1371/journal.pone.0083835
work_keys_str_mv AT prinsmarloes interleukin1bandinterleukin1receptorantagonistappearingreymatteradditionallytowhitematterlesionsduringexperimentalmultiplesclerosis
AT erikssoncharlotta interleukin1bandinterleukin1receptorantagonistappearingreymatteradditionallytowhitematterlesionsduringexperimentalmultiplesclerosis
AT wierinckxanne interleukin1bandinterleukin1receptorantagonistappearingreymatteradditionallytowhitematterlesionsduringexperimentalmultiplesclerosis
AT boljohngjm interleukin1bandinterleukin1receptorantagonistappearingreymatteradditionallytowhitematterlesionsduringexperimentalmultiplesclerosis
AT binnekaderob interleukin1bandinterleukin1receptorantagonistappearingreymatteradditionallytowhitematterlesionsduringexperimentalmultiplesclerosis
AT tildersfredjh interleukin1bandinterleukin1receptorantagonistappearingreymatteradditionallytowhitematterlesionsduringexperimentalmultiplesclerosis
AT vandamannemarie interleukin1bandinterleukin1receptorantagonistappearingreymatteradditionallytowhitematterlesionsduringexperimentalmultiplesclerosis